R1 RCM Stock Forecast, Price & News

R1 RCM's stock was trading at $10.16 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RCM shares have increased by 108.5% and is now trading at $21.18.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for R1 RCM in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for R1 RCM or view MarketBeat's top 5 stock picks.

Wall Street analysts have given R1 RCM a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but R1 RCM wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

R1 RCM is scheduled to release its next quarterly earnings announcement on Thursday, February 18th 2021.
View our earnings forecast for R1 RCM.

R1 RCM Inc. (NASDAQ:RCM) announced its earnings results on Tuesday, November, 3rd. The healthcare provider reported $0.11 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.00 by $0.11. The healthcare provider had revenue of $307.20 million for the quarter, compared to analysts' expectations of $295.38 million. R1 RCM had a net margin of 4.02% and a return on equity of 182.08%. R1 RCM's revenue was up 2.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.01 earnings per share.
View R1 RCM's earnings history.

R1 RCM updated its FY 2020 Pre-Market earnings guidance on Tuesday, November, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.25-1.26 billion, compared to the consensus revenue estimate of $1.24 billion.

5 brokerages have issued 1-year price objectives for R1 RCM's stock. Their forecasts range from $12.00 to $26.00. On average, they anticipate R1 RCM's share price to reach $19.80 in the next twelve months. This suggests that the stock has a possible downside of 6.5%.
View analysts' price targets for R1 RCM.

R1 RCM saw a decrease in short interest in November. As of November 15th, there was short interest totaling 3,790,000 shares, a decrease of 23.9% from the October 31st total of 4,980,000 shares. Based on an average daily volume of 1,540,000 shares, the days-to-cover ratio is currently 2.5 days.
View R1 RCM's Short Interest.

Some companies that are related to R1 RCM include Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), Amedisys (AMED), Chemed (CHE), LHC Group (LHCG), AMN Healthcare Services (AMN), The Providence Service (PRSC), MEDNAX (MD), CorVel (CRVL), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Biosciences (IDXG).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other R1 RCM investors own include NVIDIA (NVDA), JD.com (JD), Baozun (BZUN), Inseego (INSG), BioXcel Therapeutics (BTAI), Marvell Technology Group (MRVL), Akoustis Technologies (AKTS), Alibaba Group (BABA), Bilibili (BILI) and Model N (MODN).

R1 RCM trades on the NASDAQ under the ticker symbol "RCM."

R1 RCM's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.46%), Paradigm Capital Management Inc. NY (3.56%), State Street Corp (2.86%), SCW Capital Management LP (2.05%), Snyder Capital Management L P (1.28%) and Boston Partners (1.21%). Company insiders that own R1 RCM stock include Albert Rene Zimmerli, Charles J Ditkoff, Joseph Gerard Flanagan and Michael C Feiner.
View institutional ownership trends for R1 RCM.

RCM stock was sold by a variety of institutional investors in the last quarter, including SCW Capital Management LP, Penn Capital Management Co. Inc., Paradigm Capital Management Inc. NY, Point72 Asset Management L.P., Copper Rock Capital Partners LLC, New York State Common Retirement Fund, Royce & Associates LP, and Federated Hermes Inc..
View insider buying and selling activity for R1 RCM.

RCM stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Snyder Capital Management L P, State Street Corp, Principal Financial Group Inc., Anqa Management LLC, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, Public Sector Pension Investment Board, and Morgan Stanley. Company insiders that have bought R1 RCM stock in the last two years include Albert Rene Zimmerli, and Joseph Gerard Flanagan.
View insider buying and selling activity for R1 RCM.

Shares of RCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RCM stock can currently be purchased for approximately $21.18.

R1 RCM has a market capitalization of $2.47 billion and generates $1.19 billion in revenue each year. The healthcare provider earns $12 million in net income (profit) each year or ($0.08) on an earnings per share basis. R1 RCM employs 22,500 workers across the globe.

The official website for R1 RCM is www.r1rcm.com.

R1 RCM's mailing address is 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611. The healthcare provider can be reached via phone at (312) 324-7820 or via email at [email protected]